Reddit Posts
MDAI - “We are pleased to reach this milestone towards the initial commercialization opportunity for our DeepView AI®-Burn algorithm."
MDAI - announced the submission of an application in the United Kingdom for its predictive software DeepView AI®-Burn to be registered as UK Conformity Assessed (UKCA) for burn wound use in the UK.
MDAI - The DeepView® Wound Imaging System
MDAI nice day to accumulate with FDA pending news
MDAI nice day to accumulate with FDA pending news FDA
MDAI nice opportunity to load up today
MDAI nice week ahead...enjoy the ride
MDAI in the last post I forgot to post CTB situation
MDAI has only 240k float with 50% SI and CTB around 300%
MDAI...These things don't happen often..240k float with 50% SI and CTB around 300%.
MDAI...These things don't happen often..240k float with 50% SI and CTB around 300%..
NEGG lot of spamming posts by shorters...hope you took your profits. If you are looking for a nice squeeze MDAI is one of the best. The new hype is here.
Did you load up some MDAI in the last days...?
MDAI where could go with the squeeze and the news incoming?
MDAI very tiny float..high SI.. CTB around 300% and news incoming
MDAI accumulation is ending..nice squeeze incoming
Hope you loaded up enough MDAI 2 days ago... squeeze incoming
MDAI very tiny float ..high SI and CTB around 300%
MDAI could pop hard today with tiny float
Penny stocks to watch now? 4 turning heads this week
$MDAI micro float with +$100M in contracts
Mentions
I'm all in on PGY and MDAI. I lost logic long time ago
Check out these for scalps: 1) SES -good momentum lately 2) DGXX expecting an announcement soon I believe 3) MDAI - in overbought territory. but keeps rising up anyway. FDA approval Feb/March to Summer 4) AUR - it keeps vacillating between minor pull backs and minor surges 5) AREC if price floor thing for critical minerals is true, maybe AREC would be okay too. All of these are long term holds for me. SES and DGXX I scalp pretty much every day. AUR every other day or two.
MDAI. Buy it and forget about it until June/July. Hopefully FDA approval. Worst case scenario you lose $75.00. Best case you win $2000. Welcome to the casino.
Yup, it’s my largest holding. And it looks like depending on when you bought MDAI, you should been in the green right now 😃
This is selling after it gets FDA approval. You can swing trade shares now attempting to get a lower and lower cost basis over time. MDAI doesn’t fluctuate very much. It’s a slow mover in either direction right now.
For MDAI I’ll probably sell anything above $1.50, so that’ll be me keeping 1,100 shares. Selling 2,400 shares. May just keep 500 shares of MDAI. Depends on what the updates are around FDA approval. For ATCH, I’ll probably sell whatever is above .60. This will leave me with around 40,000 shares. Selling point will depend on momentum and updates. Don’t cut your winners too early kind of mindset. Some holdings take months to years to pan out for good returns. Penny stock traders prefer a day or few days. But I really like long term investing. I’d like to be the person who found NVDA and held for years kind of person than someone who made a quick $1000 and missed out on tens of thousands.
Thank you for the nice analysis. Where did you get the 40 million dilution number. i am seeing 71 million as of ct 2025. And there is an expectation based on what happened in 2025 that there would be an equivalent amount of dilution in 2026. [https://stonktracker.com/stock/MDAI/dilution](https://stonktracker.com/stock/MDAI/dilution)
$98 million currently, as 26 million warrants were excercised. That still leaves about 40 million warrants that can be excercised at a minimum of $1 per warrant. So further dilution is very unlikely. Current burn rate is about 7 million per quarter, although likely to increase a bit due to new, additional, trials starting soon. And yes, I believe this is my next (and hopefully biggest) money maker after RKLB, ASTS, PBC and DRTS. Bought in recently with MDAI as well.
Good old MDAI, who’s supposed to know what that means?
DGXX, HUMA, MDAI. Major catalysts inbound for all three. Already deep in the money on DGXX.
same with MDAI...using AI for burn recognition
Just opinions, definitely do your own DD/research, but these are my plays and working theses: $AMPX - my thesis for AMPX rests on a demonstrable divergence between its forensic financial reality and its distressed market valuation as of January 2026. While the market continues to price the equity as a speculative R&D venture, the company’s Q3 2025 financials confirm a commercial inflection point characterized by 173% year-over-year revenue growth and, crucially, a shift to positive 15% gross margins—a rarity for early-stage hardware firms. This margin profile validates the unit economics of their silicon anode technology, proving that industrial customers in the aviation and defense sectors are willing to pay a premium for superior energy density. Furthermore, the implementation of a capital-efficient "Fab-Light" manufacturing strategy allows for rapid backlog conversion without the immediate need for dilutive financing, creating a favorable risk-reward profile supported by a $53 million backlog and a geopolitical tailwind favoring non-Chinese battery supply chains. $DGXX - classic deep value opportunity driven by a stark disconnect between its current market capitalization and the intrinsic value of its tangible assets. The stock is currently trading at a valuation that barely exceeds its \~$100 million liquidity position, implying that the market is assigning a near-zero enterprise value to its operating business and 196.7 MW of secured power infrastructure. This creates a significant margin of safety for investors, as the debt-free balance sheet mitigates bankruptcy risk while the company executes a capital-intensive pivot from low-multiple cryptocurrency mining to high-margin AI colocation and GPU-as-a-Service. If management successfully deploys its ARMS 200 units and monetizes the recently announced 1.3 GW capacity pipeline, the stock could undergo a violent multiple expansion, re-rating from a distressed commodity play to an AI infrastructure asset. $HUMA - dislocation between price and intrinsic value, trading at a market capitalization of roughly $182 million that fails to reflect the sunk cost and strategic utility of its FDA-approved bio-manufacturing platform. The current valuation appears to price the asset solely on the immediate, friction-heavy revenue ramp of its trauma indication ignoring the "strategic put" offered by its Department of Defense ECAT listing and the substantial option value embedded in its Phase 3-validated dialysis pipeline. With a strengthened balance sheet extending the cash runway into late 2026, the market is discounting a commercial-stage biologic to near-liquidation levels, creating a highly asymmetric risk/reward profile for people (like me) willing to look past the temporary lag of hospital procurement cycles to the broader adoption curve and pipeline expansion. $MDAI - event-driven value opportunity where the market has inefficiently priced the company's transition from clinical development to commercialization. The recent contraction in equity value, driven largely by a headline decline in R&D revenue, fundamentally misinterprets the completion of pivotal government-funded trials as operational weakness rather than a necessary precursor to the FDA decision expected in the first half of 2026. With the DeepView System demonstrating statistically significant superiority over human clinical judgment in burn assessment and a liquidity runway secured through non-dilutive BARDA contracts and debt facilities, the current valuation offers an risk-reward profile that fails to account for the company's defensive IP moat and the high probability of regulatory clearance. $POET - presents a compelling long opportunity driven by its successful pivot from a capital-constrained R&D firm to a commercial manufacturer with a fortified balance sheet. The company recently secured approximately $250 million in equity financing, effectively eliminating near-term insolvency risk and providing the liquidity necessary to scale production of its Optical Interposer platform without the overhang of immediate dilution. This capital injection aligns with a critical point in the semiconductor cycle, where data center infrastructure is hitting physical limitations with copper interconnects, necessitating a shift to optical solutions 1.6T data speeds. With validated partnerships like the 1.6T optical engine collaboration with semtech and indirect exposure to Amazon’s hardware roadmap through the Marvell/Celestial AI acquisition, POET has product-market fit in a high-growth vertical. Consequently, the stock currently reflects a valuation dislocation, trading on irrelevant trailing financials rather than its emerging earnings power and strategic position within the AI hardware supply chain. I'm also long NVDA/GOOGL/IONQ.
Hey, MDAI's FDA shot and Hirsch backing scream upside, but SPAC scars and biotech vol (delays, flops) are real risks. - DYOR on de novo timelines; watch for dilution. - Diversify to hedge—biotech bets can wipe out. - Trade-off: 250-500m exit pop vs. total bust. For stable alts, DeFi like Morpho yields 5-8% on USDC. Yieldseeker on Base auto-manages passively as an option. What's your entry price?
MDAI - FDA catalyst should be dropping some time Q2 or early Q2. AI medtech.
MDAI is the the ultimate penny stock. Catch it now before it takes off!
MDAI. FDA approval expected anytime in March or before. AI imaging tech for diabetic wounds and burns. US military wants this technology yesterday. Like many biotech or biopharm stocks, I expect there will be a pre-run up to FDA approval, FDA approval spike, and then the mass sell off afterwards. Don’t expect that if the stock spikes to $4, it won’t just fall under $2 within a week. Most spikes aren’t sustained longer than a day or two. FDA approval is not assured, timeline for approval isn’t 100% by March at the latest, and you could have the market just shrug off the news. There are always risks in biopharm and biotech. I’ve got 1700 shares right now. Just slowly adding to my position, might have 3000-5000 shares as my max buy. Riskiest bet I’m in now is ATCH. They are applying to buy a fed member bank by end of this month. Could be approved. Could not be approved. Who knows what the timeline is. Will the market shrug off the news? Even though this is a fintech stock, it behaves more like a biopharm stock. But anything with batteries, energy storage, and that sort of thing is worth looking into. Datacenters, AI, drones, solar, robots, etc all need power and more of it.
Well if you are presenting a scale of worthless to completely worthless, I'd just move on. I closed out MDAI on this scale for tax purposes lol. Sometimes, especially realizing losses in Dec, is just a move on moment. In the moment the value to my portfolio was just loss. Not saying it's bad, but it was right for me here.
I'm not very active on reddit as a poster. Hence the little amount of posts. The other stock i talked about before, MDAI, is a stock i still believe in. Just waiting for FDA approval now, so it's cooling down. Still had a good profit though. Same for Rezolve. Bought earlier at 2,50, so no bags here. Just lots of opportunity.
Spectral AI. — Ticker symbol on the NASDAQ is MDAI. With a market cap of only $45 million, this stock is extremely undervalued and can easily be a 10X or 100X bagger.
Interesting DD. One thing I’d add from the drug side (vs diagnostics): FDA risk tolerance really depends on context. Elevidys is a good example. Sarepta went through a long, messy approval path because it’s a one-time gene therapy for a fatal pediatric disease. The FDA still allowed accelerated approval with post-marketing commitments because the unmet need was huge and doing nothing also carried real risk. MDAI is very different (non-invasive, diagnostic, low patient risk), which should make the bar cleaner in some ways-but FDA scrutiny doesn’t disappear, it just shifts to validation, generalizability, and real-world performance.
I did a very modest investment on 4 micro stocks suggested from this sub that after doing my own research which I thought there was long-run speculative potential— RZEN, AMPX, MDAI and ACON. So far, not so good.
100% re: selling the runner that I have learned which has been a big part of the success this year. Achr in with loads at 8.50 then out at 11.50 was a highlight earlier this year. If DFLI rips to 3 any time soon I'll drop 50% or more and go back into my drones stocks and a couple of others. If it hits 2 I'll halve my holding. Given my long term outlook I'll all about finding 5 and 10 baggers. My other 10% right now is in ATCH (down 30% rn) which is a lottery ticket but if they execute next couple of years will do well. If DFLI rips I'll buy more of those cos I'm starting to believe they're turning the corner and are well off the radar a little like DFLI. I don't generally like pharma companies but I'm vibing (your word haha) on MDAI if they get FDA approval on their AI DeepView system I reckon that one could 10-20x next few years.
GOOG was my biggest winner this year. Sold early on AMD and ASML My next high conviction plays for first semester of 2026 are PGY and MDAI
Look into MDAI next. FDA approval 99% chance Q1 2026
Well I'm stuck with $2.5 MDAI so MDAI it is... :/
MDAI as long as it get approved by the FDA, which seems likely.
What I'm watching this week - DFLI, ASST and MDAI earnings tomorrow.
Essentially a ticket which guarantees you a stock at a certain price. If you have warrants at $2, but MDAI shares are now $10. You can exercise your warrants and buy stock at $2. They do also have an expiry date so slightly riskier than buying stock
MDAI continuing to base well ahead of FDA approval and potential strategic acquisition after that
Does MDAI have a potential FDA approval date?
MDAI - just got thru raising growth capital. Clear path to fda approval and already funded by the Defense Dept. TROX - just look at the all time chart. Nice yield, cyclical low, rare earth upside.
MDAI Spectral AI looks good. Coming month can be big with the FDA approval
Thanks! I like it. Check out MDAI. They have fda approval coming up for their device. It is an easy sell to hospitals , govt. Etc. And this is where AI is very useful right now. It will save hospitals money.
I think the problem is deeper than that and using Reddit as your sole intuition on stocks will make you lag most of the time. Bynd was a nice grab here recently but overall I’m learning that Reddit mostly fails to deliver (CCCX, USAR, MDAI) and instead I’m leaning back into my own intuition. For example I think water is becoming scarce. So I’m investing in water purification companies. Or I believe in climate change, so I’m buying ac and heating stocks, lastly I want companies that are profiting year after year.
All these pump/dump is risky business! $MDAI looks solid mid-long term. Still not a bad entry point. Government contracts, FDA approval most likely and you can potentially double your money in just a few months.
MDAI holding up nicely despite the growth capital raise. Now full steam ahead to fda approval and commercialization
TMC, ADUR, BEEM, MDAI, and REKR. I’m also starting to scale into a position in SNCR. These are all in my small speculative portfolio, most of my money is either in a pension or passive funds. If you’ve got any questions about my picks, I’d be happy to answer them!
Keeping a close eye on DFLI, MDAI, NUAI the next few days
I never went to this sub before, but randomly went in too check, saw the DD on BYND and I thought it was solid enough and meme-y enough. Of course you can always buy more and there are things to regret but I managed to buy at 0.6 and some calls at 0.8. The next thing I'm looking at is $MDAI, but I mainly don't know what I'm doing.
Not for MDAI - grinding higher day by day
Never enter a stock thats already gone, its like try to enter a moving car. And dont have the mentality of ”nerd to make my money back” that will make you desperate enough to enter a new bad trade and trigger à downfall spiral. Thats doesnt mean that there isnt good stocks being recommended here and that you shouldn’t try to make your losses back but try to be smart about it. Check my latest post about MDAI, this is the kind of trades i make, i lower the risk by chosing strong stocks fundamentally that actually have legs to stand on snd then pick the right window to buy and hold. Read the post and you will get and idea of how i do it. That said, it doesnt make it bulletproof but atleast lowers the risk to a level where it makes it more rewarding than stressful. Good Luck 🫡
$MDAI showing a lot of strength today, feels like new positions are getting added and a floor is forming around $2.50. Warrants showed unusually high volume (6x average) and a 30% intraday spike. We may see upper $3 later this week/next week. This stock blows up a 50% run on a positive FDA update if I had to guess.
Great overview! I’ve been believing in this value play since mid-2024 and my portfolio is 2/3rds just this micro cap. The fundamental technology has been nothing but good news, filling a diagnostic niche for burns but also will expand to diabetic foot ulcers and I’m sure a range of other wound types. FDA approval will confirm the viability of this technology for burn and likely other indications and will make MDAI a juicy buyout target, especially with $95 million of BARDA funding getting unlocked upon approval.
Im buying MDAI Monday it’s on discount
MDAI a better bet but hope these vegan burger mofos get their bread lol
MDAI is a pump dump stock. It’s had 2 major pumps in the past 5yrs but is has also had a MASSIVE decline since its original stock price. That stock is bears and bulls playing games with each other. Sure- potential for a 2x but not reliable and you can never predict which way it’s going to go since it relies on temporary hype
I posted about SLS forever ago. (Not a penny) but also archer at $9. Posted about HIT at $0.80. Posted about MDAI still moving up. Just actually read the dd and do your own. There are still people posting about real growth potential companies. Someone posted about NUAI @ $0.48 I biught $1000 and sold because I got weak hands but just got to did through the trash and you’ll find the gold. Posted about PFSA before they had a 150% move the day before and got downvoted into oblivion. PBM and CGEN are still sleeper companies.
MDAI - SpectralAI makes DeepView which is an AI-powered scanning device that uses spectral data scans to predict burn healing to a high accuracy and creates the optimal treatment plan day 1. Trials were a huge success and now they are waiting on FDA approval by Q1 26. It is also trained on diabetic foot ulcers which is an even larger market. FDA approval odds are 80-90%, in my opinion. They are fully funded by BARDA (US gov), so there is minimal dilution risk. I see this company reaching several 100M market cap in 1 year, up to 1B in a strong scenario, and 5-10B longterm. ACON - Super tiny 4-5M market cap with 100x potential. Aclarion is run by Jeff Thramann who is a highly regarded surgeon-inventor / neurosurgeon. He has taken several companies/products to commercialization in the medical industry. Aclarion makes Nociscan which is an AI system that integrates into MRIs. For pain caused by spinal disc issues, it is often not possible to tell which (or all) of the discs are causing pain, and that results in more fused vertebrae than necessary. However, Nociscan is able to detect pain markers and directly identify the disc that's causing the pain. Previous trials were a big success and current trial is ongoing with results expected mid-2026. The trials showed higher success rate of pain reduction/surgery success vs not using Nociscan, while also being cheaper, which makes it a perfect case for adoption. Insurance companies will likely require its use. This is highly speculative obviously, but I see this possibly hitting 50M market cap (10x) in 2-3 years with potential for much more longterm if it is widely adopted. The TINY float is only 532k shares which means it will move fast on any positive headlines.
How about ORGN for under a 1$? Also i think MDAI has real potential for some room to grow with the AI boom priced around 2.60$
Brief synopsis for each. I hold them all. MDAI - 70M - SpectralAI makes DeepView which is an AI-powered scanning device that uses spectral data scans to predict burn healing to a high accuracy and creates the optimal treatment plan day 1. Trials were a huge success and now they are waiting on FDA approval by Q1 26. It is also trained on diabetic foot ulcers which is an even larger market. FDA approval odds are 80-90%, in my opinion. They are fully funded by BARDA (US gov), so there is minimal dilution risk. I see this company reaching several 100M market cap in 1 year, up to 1B in a strong scenario, and 5-10B longterm. ACON - 5M - Super tiny market cap with 100x potential. Aclarion is run by Jeff Thramann who is a highly regarded surgeon-inventor / neurosurgeon. He has taken several companies/products to commercialization in the medical industry. Aclarion makes Nociscan which is an AI system that integrates into MRIs. For pain caused by spinal disc issues, it is often not possible to tell which (or all) of the discs are causing pain, and that results in more fused vertebrae than necessary. However, Nociscan is able to detect pain markers and directly identify the disc that's causing the pain. Previous trials were a big success and current trial is ongoing with results expected mid-2026. The trials showed higher success rate of pain reduction/surgery success vs not using Nociscan, while also being cheaper, which makes it a perfect case for approval. Insurance companies will likely require its use. This is highly speculative obviously, but I see this possibly hitting 50M market cap (10x) in 2-3 years with potential for much more longterm if it is widely adopted. The TINY float is only 532k shares which means it will move fast on any positive headlines. RDZN - 100M - Roadzen is an insurtech company that makes DriveBuddyAI which helps commercial fleets and insurers detect and predict risky driver behavior, provide drowsiness alerts, score driver risk, and improve fleet safety and efficiency. Other companies have similar tech, however RDZN is uniquely positioned in India because they are the only AIS-184 certified device in the country. India also has a new law coming up next year that says all commercial vehicles must have an AIS-184 certified device installed, and RDZN is the only one with that certification. They also just got certified in EU a few days ago and just today announced a partnership with a top 5 EU carmaker. Their other revenue streams are also growing but the big catalyst for me is the India market next year which could instantly unlock 100M of revenue. I see this at $500M in a couple years, possibly sooner if their growth accelerates. The CEO recently reiterated they will turn profitable by Dec 2025 and they just raised a ton of non-dilutive cash (at a premium even), so there is very small dilution risk. AMPX - 2B - Mass drone warfare is the future, and Amprius happens to make the best drone battery on the market, competitors to SiCore are still pre-product/pre-revenue. They are in Amazon's Devices Climate Tech Program and advanced to phase 2. They will likely announce a partnership with Amazon for proprietary drone batteries. Well, this part is just my speculation, but there is no other reason for Amazon to be interested in them. They also crush every earnings. Likely 20B company in a few years. And yes of course, their batteries can do more than drones.
ALRT and MDAI for me. Both massive TAM, strong growth, evolving and unaddressed sectors, good connections with government bodies. If you want a short term potential gainer, ABVE is set to reverse merge with Palm Global, a tokenisation firm hoping to manage $1.5 Trillion worth of RWA, "launching with $350B in U.S. gold-based assets", and boarded by members of the Dubai royal family. To be honest I don't know what that values the company at, but I'm guessing it's more than the current ≈$200M ABVE is valued at.
Which app do you use to buy MDAI?
MDAI screams BUY to me. Fully funded, minimal dilution risk, likely FDA approval. One of my strongest conviction plays. Here are some basic details: SpectralAI makes DeepView which is an AI-powered scanning device that uses spectral data scans to predict burn healing to a high accuracy and creates the optimal treatment plan day 1. Trials were a huge success and now they are waiting on FDA approval by Q1 26. It is also trained on diabetic foot ulcers which is an even larger market. FDA approval odds are 80-90%, in my opinion. They are fully funded by BARDA (US gov), so there is minimal dilution risk. I see this company reaching several 100M market cap in 1 year, up to 1B in a strong scenario, and 5-10B longterm.
MDAI is doing great! The point of this question is strange, especially since you mentioned Atos. There are many other specialists. I don't like to listen to analysts, but MDAI is between $3.50 and $6. Bad valuations look different! I think it's just not moving fast enough for you. You're impatient, but I'm not a psychologist. Before you buy shares, take a close look at when the right time to enter is. Analysts at BTIG and Northland Capital Markets have reiterated their positive ratings for Spectral AI. BTIG reiterated a buy rating with a price target of $3.00 in March 2025, based on revenue of $7.6 million in the fourth quarter of 2024 and projected revenue of $21.5 million for 2025. Northland Capital Markets set a price target of $6.00 in March 2025 after the company presented promising results from a study on the DeepView® system. 🧠 Technological Innovation Spectral AI has developed its DeepView® system, a non-invasive AI-based solution that offers high accuracy in burn assessment. In a clinical study, DeepView achieved 95.3% accuracy in determining surgical burn depth, while surgeons on average only achieved 40.8%. This represents a significant advance in medical diagnostics. Reddit 💼 Financial Performance In the first quarter of 2025, Spectral AI reported net income of $2.9 million, a gross margin of 47.2%, and a 6% increase in research and development revenue to $6.7 million. The company strengthened its capital base with a $14.1 million financing, which supports its upcoming product commercialization efforts. TipRanks 🏛️ Strategic Partnerships Spectral AI received a $500,000 contract from the U.S. Defense Health Agency to develop a wearable version of the DeepView® system. This contract confirms the importance of the company's technology, particularly for solutions in battlefield burn care. Wall Street Journal 🔍 Conclusion Experts and analysts are optimistic about Spectral AI's technological innovations and financial progress. The positive reviews and strategic partnerships indicate the company's promising potential. I wish you the best of luck, stay tuned...
I’ve been accumulating since August 2024, I believe it to be way undervalued at <$100m cap, even now as my position has only increased in share count and warrant exposure. Analysts since 2024 have been giving price targets from $6-10. My personal bullish price targets are $5 upon approval and float to $10 by end of 2026. $25 for a mature burn indication revenue stream priced in. This could be priced in as soon as a year passes of burn commercialization (2027); business segment maturation in 5-7 years. My 2032 target is $400 after MDAI becomes a multi-indication global healthcare diagnostic supplier (they are already targeting US, UK, Europe, and Australia) with at least the burn and diabetic foot ulcer indications commercialized.
I’m not going to go into a full spiel on this comment, but if you’re interested, check out my previous posts on this stock. It’s my main holding in my portfolio despite its micro cap status because its story seems bulletproof. Spectral AI ($MDAI) is a pre-revenue company waiting on FDA approval of its DeepView AI burn imaging system by early 2026. They already have the studies done showcasing significant machine learning model wound healing prediction accuracy over surgeons. And their multi spectral imaging and analysis technology is scalable to healing wounds in general, their next target is the huge tens of billions market of diabetic foot ulcers. What makes this pre-revenue company different from other promising stories is that they’ve been working with the US government since 2013 on their research and development and have achieved $250 million of contractual funding, $95 million of which is unlocked to support commercialization after FDA approval. Additionally, the US government is going to acquire at least 200 of these systems automatically and begin a nice base of consistent annuity fee high-margin revenue for the company.
Spectral Ai ($MDAI) and Hyperfine ($HYPR) are two medical device companies I have high expectations for. Both of them are sub $3.00 at the moment.
These are my top plays. AMPX - 1.6B - Mass drone warfare is the future, and Amprius happens to make the best drone battery on the market, competitors to SiCore are still pre-product/pre-revenue. They are in Amazon's Devices Climate Tech Program and advanced to phase 2. They will likely announce a partnership with Amazon for proprietary drone batteries. Well, this part is just my speculation, but there is no other reason for Amazon to be interested in them. They also crush every earnings. Likely 20B company in a few years. And yes of course, their batteries can do more than drones. MDAI - 67M - SpectralAI makes DeepView which is an AI-powered scanning device that uses spectral data scans to predict burn healing to a high accuracy and creates the optimal treatment plan day 1. Trials were a huge success and now they are waiting on FDA approval by Q1 26. It is also trained on diabetic foot ulcers which is an even larger market. FDA approval odds are 90%, in my opinion. They are fully funded by BARDA (US gov), so there is minimal dilution risk. I see this company reaching several 100M market cap in 1 year, up to 1B in a strong scenario, and 5-10B longterm. ACON - 5M - Super tiny market cap with 100x potential. Aclarion is run by Jeff Thramann who is a highly regarded surgeon-inventor / neurosurgeon. He has taken several companies/products to commercialization in the medical industry. Aclarion makes Nociscan which is an AI system that integrates into MRIs. For pain caused by spinal disc issues, it is often not possible to tell which (or all) of the discs are causing pain, and that results in more fused vertebrae than necessary. However, Nociscan is able to detect pain markers and directly identify the disc that's causing the pain. Previous trials were a big success and current trial is ongoing. The trials showed higher success rate of pain reduction vs not using Nociscan, while also being cheaper, which makes it a perfect case for approval. This is highly speculative obviously, but I see this hitting 50M market cap (10x) in 2-3 years with potential for much more longterm if it is widely adopted. The TINY float is only 532k shares which means it will move FAST on any positive headlines. RDZN - 100M - Roadzen is an insurtech company that makes DriveBuddyAI which helps commercial fleets and insurers detect and predict risky driver behavior, provide drowsiness alerts, score driver risk, and improve fleet safety and efficiency. Other companies have similar tech, however RDZN is uniquely positioned in India because they are the only AIS-184 certified device in the country. India also has a new law coming up next year that says all commercial vehicles must have an AIS-184 certified device installed, and RDZN is the only one with that certification. They also just got certified in EU a few days ago and just today announced a partnership with a top 5 EU carmaker. Their other revenue streams are also growing but the big catalyst for me is the India market next year which could instantly unlock 100-200M of recurring revenue. I see this at $500M in a couple years, possibly sooner if their growth accelerates. The CEO recently reiterated they will turn profitable by Dec 2025 and they just raised a ton of non-dilutive cash (at a premium even), so there is very small dilution risk.
Loving the solid momentum on MDAI - take a look folks :)
What do you think of MDAI
MDAI interesting AH action yesterday
Thank you! I’m only in MDAI and COCH that need FDA approval for anything.
MDAI a solid legitimate opportunity
MDAI . and PDYN - that betch wanna squeeeze ! 🍋 
MDAI 🤌🏻 
So you think a stock rising this much before FDA approval won’t rise much more? Or it won’t rise enough to be worth the upside? The FDA approval is going to be a major catalyst as you have seen in here time and time again. There will be a big boom and bust. So use that event to pay off the shares you want to keep because it will most likely fall right back down. I still think it will be higher than whatever you enter at today, but no promises. But just DCA into it if you are worried. You don’t have to do large lump sums and you definitely can swing trade shares to get a better cost average over time. A recent biotech that got FDA approval is MBOT, so you can look at them as a potential reference point for the pre-FDA approval run up, the approval, the drop, the climb back up. But for more specific help and insights on MDAI, go to the MDAI Reddits. One of them uses the name Spectral AI in the name. The great news is, the US military wants this product ASAP. That is your main commercialization driver and funder. Hopefully it will lead to a less dilutive commercialization effort. They won’t have to fight tooth and nail for those first sales. They’re pretty much in the bag. The product is also highly touted by those who’ve used it for trials overseas, which is why confidence is high that Spectral AI’s tech will be approved. It’s not invasive or dangerous. The reliability of the AI is the main concern on this one. It also already made it into Time Magazine for one of the best techs in healthcare. You’re never going to find a unicorn of a stock that can avoid dilution. Execs want to be paid in stock. Mergers or acquisitions will have dilution. Getting into the Russell index will sometimes require some dilution to have more shares available to trade. Commercialization is expensive. Scaling up is expensive. Building a few MDAI units is peanuts to building thousands of them and providing software help. It’s all just a part is the journey, and this is where you pay a lot more attention to if they are being good stewards with the extra capital and doing their best to get financing on good terms instead of on toxic debt terms. The MDAI Reddit’s have timelines, videos, etc. MDAI is already working it overseas while waiting on FDA approval here. They aren’t just sitting on their hands or anything. They are already getting the word out. Spectral is a great company. Just a very quiet company. But they do make the most of every opportunity in the conferences they go to it seems like. Share prices seem to always go up after one. The main issue as a shareholder is how much money you want to have tied up while waiting on FDA approval and commercialization. I used to have 750 - 1000 shares depending on the month. I trimmed down to 100. When it’s closer to FDA approval is when I’ll load up. I just don’t want a ton of cash tied up dead for months and months. I won’t have the best cost basis, but I’ll make that money up on all the trading done on other stocks between now and then. MDAI is going go be a long term hold no matter what, just like MBOT.
Not for today but for the next year - MDAI
MDAI - govt funded med device utilizing ai to treat wounds. Already has traction in Europe and likely buyout target
Legend has it that this is the group that helps those in need by pumping their heavy baggings. The following are my bags. Please pump: IINN, MDAI, XAIR, LFMD. Thank you in advance.
Any penny stocks out there that aren't pump and dumps? Long term hold, good growth potential. What are your thoughts on MDAI?
MDAI de-SPACed in Sept. 2023.
Pretty sure his take is to the moon, why else would he be all in otherwise? I haven't seen MDAI much just saw the chart, why was there a 80% fall in September 2023?
Im basically all in on MDAI so i like the sound of this
GRAL will keep pumping, then maybe MDAI
MDAI https://preview.redd.it/fajxwo2i6atf1.jpeg?width=1320&format=pjpg&auto=webp&s=69775ad166f5c7b77c871730d9e3605314228071
Maybe MDAI, maybe not. Could be 6 mos.